# SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

> **NCT02342600** · PHASE2 · WITHDRAWN · sponsor: **Sarcoma Alliance for Research through Collaboration**

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02342600
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2020-01
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Supporting company withdrew interest
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342600, "SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02342600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*